ImmunoGen Inc. discovers and develops therapeutic monoclonal antibodies and novel treatments in the field of oncology. Its lead technology, which it refers to as tumor-activated prodrug, uses antibodies to deliver potent cell-killing agents specifically to cancer cells.

View SEC Filings from IMGN instead.
Filers who had this stock in their top 10: 0
13F Filers holding this stock: 141
Aggregate shares on 03/31/2016: 75,525,807
Aggregate shares on 12/31/2015: 77,626,877
Percent change: -2.71%
Funds creating new positions: 17
Funds Adding to an existing position: 54
Funds closing out their position: 27
Funds reducing their position: 34
View recent insider trading info

13F Filers holding this stock

Quarter 1: Refresh

Changes in Holdings:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Schedule 13D and 13G filings submitted since 03/31/2016

Subscription required

Click here to report any possible errors with this stock listing.

Elevate your investments

or Learn more